Patients and researchers question FDA cancer drug doses

Many cancer patients and clinicians are questioning the standard dosing protocols for immunotherapy drugs like nivolumab and pembrolizumab, which are often prescribed at fixed or higher doses based on initial approval. Emerging evidence suggests that lower doses or shorter treatment durations may be equally effective and could significantly reduce side effects and healthcare costs. Despite these findings, pharmaceutical companies and the U.S. healthcare system have shown limited interest in conducting formal dose-optimization studies, which could improve patient outcomes and lower expenses. Efforts are underway internationally and within some U.S. programs to explore lower dosing approaches, but widespread adoption remains limited.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل